- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | SenzaGen AB: Report from AGM of SenzaGen AB on 12 May 2026 | 184 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 12 May 2026 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 12.05. | SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods | 143 | GlobeNewswire (Europe) | Message from the CEO"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same time, we maintained our... ► Artikel lesen | |
| 15.04. | SenzaGen AB: SenzaGen's subsidiary receives strategically important order | 189 | GlobeNewswire (Europe) | SenzaGens's subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried... ► Artikel lesen | |
| 31.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 31.03.2026 | 470 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.03.2026
Aktien
1 SE0009697204 Boho Group AB
2 SE0008321608... ► Artikel lesen | |
| 30.03. | SenzaGen AB: SenzaGen wins new global cosmetics group as customer | 191 | GlobeNewswire (Europe) | SenzaGen has received a first order from a leading global group in the cosmetics sector, one of the company's prioritized industry segments. The customer will begin by testing with GARD®skin Dose-Response... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group | 156 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen's Year-End Report 2025 | SenzaGen closes the year with continued strong GARD sales | 199 | GlobeNewswire (Europe) | Message from the CEO
"As previously stated in the half-year report, 2025 performance was stronger in the second half of the year. GARD® continued to strengthen its market position with positive sales... ► Artikel lesen | |
| 16.12.25 | SenzaGen AB: SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader | 181 | GlobeNewswire (Europe) | SenzaGen continues to solidify its role as an important partner for customers with high safety testing requirements, securing an assignment worth approximately 1.5 MSEK from a leading American chemical... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | SenzaGen AB: SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan | 185 | GlobeNewswire (Europe) | To support its recently announced growth strategy through 2030, SenzaGen has opened expanded office and laboratory facilities in Lund. This investment strengthens the company's ability to meet the growing... ► Artikel lesen | |
| 18.11.25 | SenzaGen AB: UK signals shift to non-animal testing - new opportunities for SenzaGen | 192 | GlobeNewswire (Europe) | The UK government has recently unveiled a national strategy to accelerate the phase-out of animal testing in research and product development. The plan includes clear timelines and governance to ensure... ► Artikel lesen | |
| 05.11.25 | SenzaGen AB: SenzaGen's interim report January-September 2025 | Growth and break-even in Q3 | 169 | GlobeNewswire (Europe) | Message from the CEO"We delivered a strong third quarter in line with our expectations, with higher sales and significantly improved EBITDA, both sequentially and year on year, which I am pleased to... ► Artikel lesen | |
| 22.08.25 | SenzaGen AB: SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD from a global leading U.S. pharmaceutical company | 239 | GlobeNewswire (Europe) | SenzaGen has received a new follow-up order from a global leader in the pharmaceutical and life science industry. The order, valued at approximately 1.0 million SEK, covers testing with GARD®air, SenzaGen's... ► Artikel lesen | |
| 20.08.25 | SenzaGen AB: SenzaGen's interim report January-June 2025 | Strong order intake and expanded OECD approval for GARDskin | 353 | GlobeNewswire (Europe) | Message from the CEO
"We continue to win new customers, and our order intake is significantly higher than our sales for the period, giving us a strong starting position for the coming quarters. Given... ► Artikel lesen | |
| 30.06.25 | SenzaGen AB: SenzaGen obtains expanded OECD approval for GARDskin - further strengthens position in non-animal regulatory testing | 381 | GlobeNewswire (Europe) | SenzaGen's non-animal test method GARD®skin, which has been approved since 2022 under OECD Test Guideline TG 442E, has now also been included in the newly introduced OECD TG 497. This international... ► Artikel lesen | |
| 24.06.25 | SenzaGen AB: SenzaGen receives new assignment worth 1.5 MSEK from RIFM for continued collaboration in photosensitization testing | 229 | GlobeNewswire (Europe) | SenzaGen has been awarded a new grant worth 1.5 MSEK from the Research Institute for Fragrance Materials (RIFM), a leading international research institute in fragrance safety. The assignment involves... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 15,710 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,820 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,790 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| EDGEWISE THERAPEUTICS | 40,290 | +0,07 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,820 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,100 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| TYRA BIOSCIENCES | 30,390 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| IMMUNOME | 20,780 | 0,00 % | Immunome: Phase-3-Studie zu Varegacestat zeigt hohe Wirksamkeit bei Desmoid-Tumoren | ||
| IMMUNOVANT | 32,830 | -0,09 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| INHIBRX BIOSCIENCES | 99,29 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| JADE BIOSCIENCES | 18,625 | +0,19 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,510 | 0,00 % | Mizuho raises Enliven Therapeutics stock price target on trial data | ||
| BEAM THERAPEUTICS | 31,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| CG ONCOLOGY | 59,25 | +0,03 % | CG Oncology, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 335,12 | -0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen |
Das Unternehmen SENZAGEN AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,485 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.